called MuSK. And then there's a rarer type LRP4 plus against lipoprotein. Between those 3, you account for maybe 95% of all myasthenia gravis cases. So what does that do to you? It effectively ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Individuals Affected by Myasthenia Gravis produce antibodies against acetylcholine receptors (AChR-Ab) or against a protein called muscle-specific tyrosine kinase (MuSK-Ab). This disease affects ...

a treatment for generalized myasthenia gravis (gMG) in antibody-positive patients, including those with anti-AChR, anti-MuSK, and anti-LRP4 antibodies. The Priority Review designation applies to ...

Fintel reports that on February 4, 2025, Baird initiated coverage of Catalyst Pharmaceuticals (NasdaqCM:CPRX) with a ...

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one ... specific tyrosine kinase (MuSK) antibody positive.

I'm Dr. John Whyte, the Chief Medical Officer of WebMD. Today, I want to talk about a serious autoimmune condition called myasthenia gravis. It comes from the Latin and Greek which means grave ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor [AChR], anti-muscle-specific tyrosine kinase [MuSK] or ...

Myasthenia gravis and myasthenic syndromes ... Fewer thymic changes in MuSK-positive than in MuSK-negative MG. Ann Neurol 2005; 57: 444–48. MEDLINE 13. Ströbel P, Marx A, Zettl A, Müller ...